返回 
加入收藏
紫杉醇、顺铂联合重组人血管内皮抑制素对非小细胞肺癌患者的疗效及相关指标的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 紫杉醇、顺铂联合重组人血管内皮抑制素对非小细胞肺癌患者的疗效及相关指标的影响 |
| TITLE： | |
| 摘要： | 目的：探讨紫杉醇、顺铂联合重组人血管内皮抑制素对非小细胞肺癌（NSCLC）患者的疗效及相关指标的影响。方法：78例NSCLCⅢb期或Ⅳ期患者随机分为对照组（39例）和观察组（39例）。对照组患者给予紫杉醇注射液135～175 mg/m2，d1，静脉滴注，每日1次+顺铂注射液25 mg/m2，d1-3，静脉滴注，每日3次。观察组患者在对照组治疗的基础上给予重组人血管内皮抑制素注射液15 mg/m2，加入0.9％氯化钠注射液500 ml中，缓慢静脉滴注3～4 h，d1-14，后停用7 d。两组均以21 d为1个周期，共治疗6个周期。观察两组患者的临床疗效，治疗前后程序性死亡配体-1（PD-L1）水平、生存质量（QOL）评分及不良反应发生情况。结果：两组患者均完成2周期化疗。观察组有3例患者、对照组有4例患者因不能耐受或药物不良反应未完成6个周期化疗而退出本研究。观察组患者总缓解率显著高于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者PD-L1水平、QOL评分比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者PD-L1水平、QOL评分均显著低于同组治疗前，且观察组低于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较差异无统计学意义（P＞0.05）。结论：紫杉醇、顺铂联合重组人血管内皮抑制素可提高NSCLC患者的近期疗效，抑制PD-L1表达，改善生存质量，且不增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To observe the effects of Paclitaxel， Cisplatin combined with Recombinant human （Rh） endostatin on the efficacy and related indexes of patients with non-small cell lung cancer （NSCLC）. METHODS： 78 patients with Ⅲb or Ⅳ NSCLC were randomly divided into control group （39 cases） and observation group （39 cases）. Control group received Paclitaxel injection 135-175 mg/m2， d1， intravenous infusion，once a day+Cisplatin injection 25 mg/m2， 3 times a day， d1-3， intravenous infusion. Observation group additionally received Rh endostatin injection 15 mg/m2， adding into 500 ml 0.9％ Sodium chloride injection by slow intravenous infusion 3-4 h，d1-14， then stopped for 7 d. 21 d was regarded as 1 treatment course， it lasted 6 courses. Clinical efficacy， programmed death ligand-1（PD-L1） level， quality of life （QOL） score before and after treatment， and the incidence of adverse reactions in 2 groups were observed. RESULTS： All patients completed 2 courses of chemotherapy. There were 3 patients in observation group and 4 patients in control group quitted the study with uncompleted 6 weeks of chemotherapy due to intolerance or adverse reactions. The remission rate in observation group was significantly higher than control group， with statistical significance （P＜0.05）. Before treatment， there were no significant differences in PD-L1 level and QOL score in 2 groups （P＞0.05）. After treatment， PD-L1 level and QOL score in 2 groups were significantly lower than before， and observation group was lower than control group， with statistical significance （P＜0.05）. And there was no significant difference in the incidence of adverse reactions in 2 groups （P＞0.05）. CONCLUSIONS： Paclitaxel， Cisplatin combined with Rh endostatin can improve the short-term efficacy of patients with NSCLC， inhibit PD-L1 expression， improve QOL， and do not increase the incidence of adverse reactions. |
| 期刊： | 2016年第27卷第30期 |
| 作者： | 张金忠，牟坤，王继松 |
| AUTHORS： | ZHANG Jinzhong，MOU Kun，WANG Jisong |
| 关键字： | 重组人血管内皮抑制素；紫杉醇；顺铂；非小细胞肺癌；疗效；安全性；程序性死亡配体-1 |
| KEYWORDS： | Recombinant human endostatin； Paclitaxel； Cisplatin； Non-small cell lung cancer； Efficacy； Safety； Programmed death-ligand1 |
| 阅读数： | 264 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
